# Pizarra — PT-pseudo_d3e975d025e6 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3e975d025e6
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 15.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.318 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 15.4 ng/mL
  - Prostate volume: 49.63 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84823215 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.

Vitals: weight 69 kg, height 179 cm, BMI 21.5, BP 127/86 mmHg, HR 72 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results.

History: First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly.

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.83 +/- 0.14   (95% CI 0.47-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 5.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=15.8, age=67.0, psad=0.318, dre_ord=1.0, vol=49.63, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.96 ng/mL/yr), the specific details of the mpMRI report (beyond PI-RADS 5), or the full laboratory panel/PSA history trend, which are critical for assessing the rate of progression and overall risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.83), but the PI-RADS 5 is high, yet the prior biopsy status is 'None'. The high csPCa probability (0.848) combined with a DRE finding of 'Nodus' (which is ambiguous) might be contradicted by the actual findings in the mpMRI report or the PSA velocity. The prior's confidence is based on limited data, and the wide interval (0.47-0.99) suggests high uncertainty, meaning the prior's strong suggestion could be easily overturned by missing context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details highly suspicious features or excludes clinically significant cancer, it would strongly shift the decision away from biopsy.
  <document> PSA history (trend) -> If the PSA velocity is very high or if the trend is rapidly increasing, it would increase the urgency for biopsy.
  <document> laboratory results (full panel) -> If there are any concerning laboratory markers (e.g., elevated PSA density or other markers), it would modify the risk assessment.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial PSA elevation or any prior clinical suspicion that the structured panel missed.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_d3e975d025e6", "radiology_report": "Jeroen Bosch Ziekenhuis, 's-Hertogenbosch | 15 January 2025 | mpMRI of the Prostate\n\nClinical indication: Evaluation of persistently elevated PSA (15.8 ng/mL) and clinical suspicion of malignancy.\n\nFINDINGS:\nA glandular capacity of 49.63 mL is recorded. Imaging reveals a discrete, low-signal area within the left peripheral zone, spanning the base through the mid-gland, spanning roughly 18 mm at its widest. High b-value diffusion sequences show intense restriction, mirrored by dark ADC mapping. Post-contrast phases highlight early, localized enhancement compared to adjacent tissue. Capsular integrity remains intact with no seminal vesicle involvement. Pelvic nodes show normal dimensions and structure. No abnormal bone signals appear in the scanned region.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm. Prostate volume 49.63 mL. PSA density 0.318 ng/mL/mL. csPCa probability 0.84823215."}

  **psa_trend**
  {"case_id": "PT-pseudo_d3e975d025e6", "psa_trend": [{"date": "Jan 2023", "val": 3.9}, {"date": "Jul 2023", "val": 5.5}, {"date": "Jan 2024", "val": 7.8}, {"date": "Jul 2024", "val": 11.1}, {"date": "Jan 2025", "val": 15.8}]}

  **laboratory results**
  {"case_id": "PT-pseudo_d3e975d025e6", "laboratory_results": [{"name": "PSA", "val": "15.8 ng/mL", "date": "13 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.45 ng/mL", "date": "13 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "13 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.8 g/dL", "date": "13 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.8 x10^9/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "241 x10^9/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "88 umol/L", "date": "13 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "13 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "16.3 nmol/L", "date": "13 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "71 U/L", "date": "13 Dec 2024", "flag": ""}, {"name": "LDH", "val": "186 U/L", "date": "13 Dec 2024", "flag": ""}]}

  **previous GP / urology consultation notes**
  {"case_id": "PT-pseudo_d3e975d025e6", "previous_notes": [{"date": "24 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "Clinical review on 24 January 2024 documented a PSA level of 15.1 ng/mL, following values of 11.6 ng/mL in early 2023 and a peak reading of 22.1 ng/mL during mid-2023. Persistent elevation alongside a fluctuating trajectory led to urological referral for comprehensive assessment and potential multiparametric MRI scheduling. Repeat laboratory work confirmed stable renal parameters. The outpatient visit was coordinated for his preferred morning window."}]}

NOT RETRIEVED
  get_family_history - Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm.
  PSA velocity of 0.96 ng/mL/yr, indicating a rapid rise in PSA.
  csPCa predicted probability of 0.84823215.
  Previous notes documenting a fluctuating trajectory and referral for MRI.

  AGAINST sampling this patient now:
  %Free PSA of 16% (which is generally a favorable prognostic indicator).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high PI-RADS score (5), the high PSA velocity (0.96 ng/mL/yr), and the high predicted csPCa probability (0.848). This contradicts the potentially favorable %Free PSA finding.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high PI-RADS 5 lesion in the left peripheral zone and the rapid PSA velocity of 0.96 ng/mL/yr, which strongly indicate high-risk disease. This is supported by the high csPCa predicted probability of 0.848 and the PI-RADS 5 score being decisive. Although the %Free PSA is 16%, the aggressive trajectory and high imaging score outweigh this factor, leading to a clear recommendation for sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
